Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

Florian Rieder, Vice-Chair, Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic

“I am pleased to present the OLE data at UEG Week, which provide important insights into extended treatment with ontunisertib. The findings highlight the potential of ontunisertib to provide a meaningful clinical benefit for people living with FSCD. I also look forward to joining leading experts in the symposium on fibro-inflammation and discussing how a deeper understanding of the crosstalk between inflammation and fibrosis may help advance therapeutic approaches for patients facing therapeutic resistance and progressive bowel damage.”

Philippe Wiesel, Chief Medical Officer of Agomab

“The oral presentation of the STENOVA OLE data at UEG Week provides an important opportunity to share the growing body of evidence supporting ontunisertib in FSCD with the global gastroenterology community. The OLE results reinforce our confidence in the potential of ontunisertib as we advance the global Phase 2b NOV-ERA study in the coming months. We are also delighted to convene leading experts for a discussion on fibro-inflammation, a rapidly evolving area of science that is reshaping our understanding of disease progression in IBD.”